Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: Achilles' Last Stand?

Daniel W Carlson; Ronald D Berger

doi:10.1016/j.jacep.2017.10.005

Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: Achilles' Last Stand?

JACC Clin Electrophysiol. 2017 Dec 26;3(13):1484-1486. doi: 10.1016/j.jacep.2017.10.005. Epub 2017 Nov 29.

Authors

Daniel W Carlson¹, Ronald D Berger²

Affiliations

¹ Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
² Department of Medicine, Johns Hopkins University, Baltimore, Maryland. Electronic address: rberger@jhmi.edu.

PMID: 29759828
DOI: 10.1016/j.jacep.2017.10.005

No abstract available

Keywords: device infection; implantable cardioverter-deﬁbrillator shock; inappropriate therapy; subcutaneous implantable cardioverter; transvenous implantable cardioverter-deﬁbrillator.

Publication types

Editorial
Comment

MeSH terms

Case-Control Studies
Death, Sudden, Cardiac
Defibrillators, Implantable*
Humans
Ventricular Fibrillation